Inhaled fluticasone furoate falls flat in speeding up COVID-19 recovery, says ACTIV-6 trial

The ACTIV-6 trial investigated the effectiveness of inhaled fluticasone furoate on mild-to-moderate COVID-19 cases and found it did not accelerate recovery or prevent clinical progression compared to a placebo. Interestingly, vaccinated participants showed slightly faster recovery when treated with the drug, while unvaccinated participants did not.

Scoop: Resilience downsizes technical R&D and quality assurance divisions

National Resilience has laid off staff from its technical R&D and quality assurance global divisions in recent months, Endpoints News has learned. The manufacturer confirmed

December 21, 2023

Sandoz opens two new facilities; Gates Foundation funds needle-free vaccines; Novartis expands Japanese site

Welcome to Endpoints News’ manufacturing news briefs, where we bring you essential updates on new builds, collaborations, recalls and more. Sandoz inaugurated two separate facilities

November 17, 2023

COMPASS Pathways Secures Large Funding To Fund Phase 3 Psilocybin Assisted Therapy Trial

COMPASS Pathways plc (Nasdaq: CMPS) made a significant announcement that could secure most, or all, of the funding needed to conduct their ongoing Phase 3

August 17, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.